Resverlogix Corp. (RVXCF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -11.74 Million USD | 21.02% |
| 2021 | -14.86 Million USD | 0.0% |
| 2019 | -21.92 Million USD | -125.5% |
| 2018 | 85.99 Million USD | 381.57% |
| 2017 | -30.54 Million USD | -5.98% |
| 2016 | -28.81 Million USD | -9.93% |
| 2015 | -26.21 Million USD | -741.84% |
| 2014 | -3.11 Million USD | -104.24% |
| 2013 | 73.4 Million USD | 179.62% |
| 2012 | 26.25 Million USD | -15.15% |
| 2011 | 30.94 Million USD | 243.37% |
| 2010 | -21.58 Million USD | 17.08% |
| 2009 | -26.02 Million USD | -58.9% |
| 2008 | -16.37 Million USD | 32.76% |
| 2007 | -24.35 Million USD | -58.52% |
| 2006 | -15.36 Million USD | -150.38% |
| 2005 | -6.13 Million USD | -122.68% |
| 2004 | -2.75 Million USD | -114.59% |
| 2003 | -1.28 Million USD | -161.99% |
| 2002 | -490.2 Thousand USD | -161.92% |
| 2001 | -187.15 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -911 Thousand USD | 33.99% |
| 2023 Q2 | -1.38 Million USD | 0.0% |
| 2022 Q4 | -2.29 Million USD | -14.44% |
| 2022 Q2 | -1.75 Million USD | 69.03% |
| 2022 FY | - USD | 21.02% |
| 2022 Q3 | -2 Million USD | -14.28% |
| 2022 Q1 | -5.67 Million USD | -5.82% |
| 2021 Q4 | -5.36 Million USD | -8.32% |
| 2021 Q1 | -1.37 Million USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q2 | -3.17 Million USD | -131.22% |
| 2021 Q3 | -4.95 Million USD | -55.87% |
| 2020 Q3 | -3.25 Million USD | 10.7% |
| 2020 Q1 | -1.37 Million USD | 70.95% |
| 2020 Q2 | -3.64 Million USD | -164.97% |
| 2019 FY | - USD | -125.5% |
| 2019 Q4 | -4.73 Million USD | 86.56% |
| 2019 Q3 | -35.23 Million USD | -49.32% |
| 2019 Q2 | -23.59 Million USD | -153.36% |
| 2019 Q1 | 44.22 Million USD | 757.86% |
| 2018 Q3 | 15.88 Million USD | -51.26% |
| 2018 Q1 | -12.6 Million USD | -331.17% |
| 2018 Q2 | 32.6 Million USD | 358.68% |
| 2018 Q4 | -6.72 Million USD | -142.31% |
| 2018 FY | - USD | 381.57% |
| 2017 Q3 | -10.6 Million USD | -140.27% |
| 2017 FY | - USD | -5.98% |
| 2017 Q4 | -2.92 Million USD | 72.43% |
| 2017 Q1 | -9.71 Million USD | -20.44% |
| 2017 Q2 | -4.41 Million USD | 54.56% |
| 2016 FY | - USD | -9.93% |
| 2016 Q1 | -7.04 Million USD | -247.41% |
| 2016 Q3 | -1.65 Million USD | 82.34% |
| 2016 Q4 | -8.06 Million USD | -386.66% |
| 2016 Q2 | -9.38 Million USD | -33.13% |
| 2015 Q4 | -2.02 Million USD | 65.77% |
| 2015 Q3 | -5.92 Million USD | 47.13% |
| 2015 Q1 | 19.15 Million USD | 600.86% |
| 2015 Q2 | -11.21 Million USD | -158.53% |
| 2015 FY | - USD | -741.84% |
| 2014 FY | - USD | -104.24% |
| 2014 Q4 | -3.82 Million USD | -459.88% |
| 2014 Q3 | -683 Thousand USD | 38.36% |
| 2014 Q2 | -1.1 Million USD | -115.4% |
| 2014 Q1 | 7.19 Million USD | 136.05% |
| 2013 Q4 | -19.95 Million USD | -497.69% |
| 2013 Q1 | 5.69 Million USD | 26.79% |
| 2013 Q2 | 42.85 Million USD | 652.7% |
| 2013 Q3 | -3.33 Million USD | -107.79% |
| 2013 FY | - USD | 179.62% |
| 2012 Q1 | -6.68 Million USD | -246.46% |
| 2012 Q2 | 9.3 Million USD | 239.11% |
| 2012 FY | - USD | -15.15% |
| 2012 Q3 | 6.76 Million USD | -27.24% |
| 2012 Q4 | 4.49 Million USD | -33.63% |
| 2011 Q4 | 4.56 Million USD | 169.97% |
| 2011 Q1 | -6.64 Million USD | -38.73% |
| 2011 Q2 | -5.22 Million USD | 21.42% |
| 2011 Q3 | -6.52 Million USD | -24.89% |
| 2011 FY | - USD | 243.37% |
| 2010 Q2 | -24.26 Million USD | -341.14% |
| 2010 Q4 | -4.79 Million USD | -135.36% |
| 2010 FY | - USD | 17.08% |
| 2010 Q1 | -5.5 Million USD | -21.3% |
| 2010 Q3 | 13.55 Million USD | 155.85% |
| 2009 Q4 | -4.53 Million USD | -17.44% |
| 2009 FY | - USD | -58.9% |
| 2009 Q3 | -3.86 Million USD | 15.58% |
| 2009 Q2 | -4.57 Million USD | -22.9% |
| 2009 Q1 | -3.72 Million USD | 23.5% |
| 2008 FY | - USD | 32.76% |
| 2008 Q2 | -4.12 Million USD | 42.03% |
| 2008 Q3 | -4.66 Million USD | -13.1% |
| 2008 Q4 | -4.86 Million USD | -4.25% |
| 2008 Q1 | -7.11 Million USD | -38.53% |
| 2007 FY | - USD | -58.52% |
| 2007 Q3 | -6.54 Million USD | -22.75% |
| 2007 Q2 | -5.33 Million USD | 29.95% |
| 2007 Q1 | -7.61 Million USD | -116.93% |
| 2007 Q4 | -5.13 Million USD | 21.56% |
| 2006 Q1 | -1.98 Million USD | -62.64% |
| 2006 FY | - USD | -150.38% |
| 2006 Q2 | -1.69 Million USD | 14.44% |
| 2006 Q3 | -2.74 Million USD | -61.4% |
| 2006 Q4 | -3.51 Million USD | -28.03% |
| 2005 Q3 | -1.71 Million USD | -60.27% |
| 2005 FY | - USD | -122.68% |
| 2005 Q2 | -1.07 Million USD | -16.79% |
| 2005 Q1 | -918.88 Thousand USD | -3.35% |
| 2005 Q4 | -1.22 Million USD | 29.01% |
| 2004 Q1 | -687.76 Thousand USD | -231.34% |
| 2004 FY | - USD | -114.59% |
| 2004 Q2 | -414.94 Thousand USD | 39.67% |
| 2004 Q3 | -263.06 Thousand USD | 36.6% |
| 2004 Q4 | -889.12 Thousand USD | -237.99% |
| 2003 Q1 | -230.68 Thousand USD | -147.84% |
| 2003 Q3 | -114.85 Thousand USD | 55.29% |
| 2003 Q4 | -207.57 Thousand USD | -80.72% |
| 2003 Q2 | -256.9 Thousand USD | -11.37% |
| 2003 FY | - USD | -161.99% |
| 2002 Q3 | -12.95 Thousand USD | 49.44% |
| 2002 Q4 | -93.07 Thousand USD | -618.48% |
| 2002 Q2 | -25.62 Thousand USD | -436.37% |
| 2002 Q1 | -4777.27 USD | 0.0% |
| 2002 FY | - USD | -161.92% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 83.47% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -98.047% |
| SQZ Biotechnologies Company | -64.14 Million USD | 81.693% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 32.401% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 112.486% |
| Mesoblast Limited | -62.38 Million USD | 81.18% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -664.429% |
| Genus plc | 73.7 Million USD | 115.932% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -77.599% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -231.041% |
| Marizyme, Inc. | -34.28 Million USD | 65.748% |
| ContraFect Corporation | -64.99 Million USD | 81.935% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -33.858% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -159.423% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -737.633% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -344.025% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -405.289% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2166.594% |
| Accustem Sciences Inc. | -3.74 Million USD | -213.419% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 75.653% |
| EV Biologics, Inc. | -1.26 Million USD | -826.66% |
| Q BioMed Inc. | -617.62 Thousand USD | -1801.144% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 428.723% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1756.719% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -413.988% |
| Biomind Labs Inc. | -1.03 Million USD | -1034.987% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 218.882% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -63.965% |
| Skye Bioscience, Inc. | -13.54 Million USD | 13.328% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -689.425% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -46868.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -202.292% |
| IMV Inc. | -35.52 Million USD | 66.946% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 26.01% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -369.312% |
| GB Sciences, Inc. | -1.41 Million USD | -726.968% |
| Alpha Cognition Inc. | -9.7 Million USD | -20.982% |
| HST Global, Inc. | -5303.00 USD | -221321.837% |
| CSL Limited | 4.78 Billion USD | 100.245% |
| Halberd Corporation | -74.27 Thousand USD | -15707.967% |
| Enzolytics Inc. | -2.12 Million USD | -453.338% |
| Affymax, Inc. | -14.29 Million USD | 17.859% |
| SYBLEU INC | -141.57 Thousand USD | -8194.072% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -283.348% |
| argenx SE | -216.02 Million USD | 94.564% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 78.782% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1064.832% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -683.371% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3199.429% |
| AVAX Technologies, Inc. | -6.11 Million USD | -92.094% |
| Zenith Capital Corp. | -8.6 Million USD | -36.44% |
| Genscript Biotech Corporation | -248.71 Million USD | 95.279% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -67301.412% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -379.959% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -6570.668% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 70.376% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -305.971% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1022.227% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 174728.198% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -570.972% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -511.272% |
| BioStem Technologies, Inc. | -7.55 Million USD | -55.448% |
| ONE Bio Corp. | 13.61 Million USD | 186.256% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -6384.14% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -470.831% |
| Agentix Corp. | -1.37 Million USD | -755.983% |
| LadRx Corporation | 412.28 Thousand USD | 2948.044% |
| Cell Source, Inc. | -4.27 Million USD | -174.826% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3097.53% |
| Regen BioPharma, Inc. | 1.46 Million USD | 900.979% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1153.217% |
| NovAccess Global Inc. | -1.03 Million USD | -1034.715% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 232.621% |
| Itoco Inc. | -1.86 Million USD | -528.252% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2993.093% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -952.151% |
| Kadimastem Ltd | -2.62 Million USD | -347.42% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -4809.889% |
| CytoDyn Inc. | -18.02 Million USD | 34.872% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -14757.837% |
| Mobile Lads Corp. | -2.24 Million USD | -423.925% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -95917.663% |
| Qrons Inc. | -40.08 Thousand USD | -29195.676% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2317.651% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2326.254% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1134.7% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1005.639% |
| International Stem Cell Corporation | 202 Thousand USD | 5912.871% |
| Bioxytran, Inc. | -3.82 Million USD | -207.37% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -22206.231% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -376.942% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 67.264% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -25993.333% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -328.853% |
| Neutra Corp. | -181.24 Thousand USD | -6378.452% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 41.753% |
| PureTech Health plc | -11.62 Million USD | -0.989% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 41.749% |
| IXICO plc | -707 Thousand USD | -1560.82% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -52.791% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 75.713% |
| CSL Limited | 4.73 Billion USD | 100.248% |
| Cellectis S.A. | -92.63 Million USD | 87.325% |